Instead of watching our canine companions succumb to the inevitable decline of age-related disease, the rapidly advancing field of canine geroscience is proactively targeting the biological roots of aging. At the forefront of this movement is a highly targeted pharmacological intervention: using rapamycin to selectively inhibit the mechanistic target of rapamycin (mTOR) pathway. By dialing…

People are tracking the latest breakthroughs in clinical longevity, already know that rapamycin has shifted from a niche immunosuppressant to the most heavily debated molecule in geroscience. But exactly why would a doctor prescribe rapamycin today? For decades, the FDA has approved rapamycin (known generically as sirolimus) specifically to prevent organ transplant rejection and treat…

Optimizing a Rapamycin Protocol for healthy aging is rapidly shifting from speculative biohacking to a data-driven clinical science. As more normative aging individuals look to geroprotective compounds, physicians and researchers are moving beyond the theoretical mechanisms of mTOR inhibition to focus on real-world pharmacokinetics, bioavailability, and precise dosing regimens. You are likely already aware that…

The translation of mammalian target of rapamycin (mTOR) inhibitors from preclinical models to human longevity interventions is the most scrutinized frontier in modern geroscience. We are moving far beyond the theoretical question of if rapamycin extends lifespan. Decades of data confirm its efficacy across yeast, nematodes, fruit flies, and mice. Today, the clinical challenge is…

When integrating geroprotective compounds into a longevity protocol, individuals frequently encounter a paradoxical side effect: drug-induced dyslipidemia. Specifically, patients optimizing for healthspan often experience unexpected spikes in apolipoprotein B (ApoB), low-density lipoprotein (LDL), and triglycerides. Addressing rapamycin and lipids: how to manage high triglycerides while on it is critical, as ignoring cardiovascular risk factors can…

Rapamycin inhibits mTORC1, raising concerns it might blunt muscle protein synthesis and hypertrophy from exercise. Recent studies show acute rapamycin blocks early post-exercise protein synthesis spikes in humans, but chronic low-dose or intermittent use often preserves gains, especially with strategic timing around workouts. Explore protocols balancing longevity benefits with muscle goals at Rapashop.net for pure,…

"They might increase lifespan by a little bit or they might increase it by a lot,” says Tahlia Fulton at the University of Sydney in Australia. Introduction The quest to extend healthy human lifespan has long captivated biomedical science, yet few interventions have generated as much rigorous scientific interest as rapamycin. First described in the 1970s as…

Recent studies show rapamycin extends lifespan in animals comparably to dietary restriction like intermittent fasting, but human data remains limited with both offering mTOR inhibition benefits. No clear winner emerges yet—rapamycin may edge out in late-life starts, while fasting proves more accessible. This post dives into mechanisms, trials, and real-world insights to help you weigh…

Rapamycin shows promise in slowing or partially reversing epigenetic clocks in preclinical models like human skin cells and mice, however human clinical evidence remains limited and mixed. Experts like Matt Kaeberlein highlight ongoing dog trials as key tests for translation, while users report variable biomarker shifts alongside side effects. This post dives into mechanisms, data,…

Rapamycin inhibits mTORC1 rapidly but can disrupt mTORC2 with prolonged or high exposure, potentially leading to insulin resistance, immune suppression, and endothelial damage—serious risks for longevity seekers. Intermittent low dosing minimizes mTORC2 impact while preserving benefits like autophagy induction. Experts like Peter Attia and Matt Kaeberlein advocate pulsed protocols to balance these effects. How Does…